Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Navigating Payers’ Expectations for Value-Based Agreements

As biomedical innovation has developed advanced therapeutic modalities and prospective cures for ailments that previously had no comparable courses of treatment, the challenge of crafting sustainable reimbursement models has inspired a variety of value-based agreements. Departure from traditional dosage-based models makes it difficult for therapy developers, payers, patients, and investors to plan for a new therapy’s rollout and breadth of patient access. This session will explore the early lessons from current value-based agreements to explain the payers’ expectations for future models of reimbursing treatments based on outcomes versus delivery.

Moderator: Yasmeen Rahimi, Managing Director and Senior Research Analyst Biotechnology, ROTH Capital Partners

  • Date:Monday, February 11
  • Time:1:30 PM - 2:25 PM
  • Room:Shubert Complex
  • Location:6th Floor
  • Session Type:Educational Panel
  • Please submit your session questions in advance at:http://bit.ly/BIOCEO19question
Speakers
Yasmeen Rahimi
ROTH Capital Partners
R. John Glasspool
Massachusetts Institute of Technology
Roger Longman
Real Endpoints
Ron Philip
Spark Therapeutics
Back